menu
    • menu
    [{"orgOrder":0,"company":"SK Bioscience","sponsor":"Doherty Institute","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"SOUTH KOREA","productType":"Vaccine","year":"2023","type":"Collaboration","leadProduct":"Quadrivalent Cell Culture-based Influenza Vaccine","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Discovery","graph3":"SK Bioscience","amount2":0,"highestDevelopmentShortName":"Discovery","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"SK Bioscience \/ Doherty Institute","highestDevelopmentStatusID":"2","companyTruncated":"SK Bioscience \/ Doherty Institute"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SK Bioscience

                            South Korea arrow
                            AusBiotech
                            Not Confirmed

                            SK Bioscience

                            South Korea arrow
                            AusBiotech
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Quadrivalent Cell Culture-based Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Doherty Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SK Bioscience and the Peter Doherty Institute for Infection and Immunity Join Forces Against Influenza

                            Details : SK bioscience and the Doherty Institute will work to support and research in influenza biology, vaccines and antivirals. The program includes testing of anti-influenza compounds to identify new antivirals and development of quadrivalent cell culture-base...

                            Product Name : Undisclosed

                            Product Type : Vaccine

                            Upfront Cash : Undisclosed

                            June 27, 2023

                            Lead Product(s) : Quadrivalent Cell Culture-based Influenza Vaccine

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Doherty Institute

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Celltrion

                            South Korea arrow
                            AusBiotech
                            Not Confirmed

                            Celltrion

                            South Korea arrow
                            AusBiotech
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Discovery

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celltrion Accelerates Development of COVID-19 Antiviral Treatment and Aims to Launch Rapid Self-testing Kit

                            Details : Celltrion achieved the first step of developing an antiviral treatment to fight COVID-19 and Plans to launch a fast self-testing diagnostic kit that could provide results within 15-20 minutes.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            March 23, 2020

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Discovery

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth